ASX:NC6

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Nanollose Limited, a biotechnology company, engages in the research and development, and promotion of the microbial nanocellulose technology in Australia. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Nanollose's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NC6 is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: NC6's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.


Market Performance


7 Day Return

-1.6%

NC6

2.8%

AU Biotechs

2.3%

AU Market


1 Year Return

-12.9%

NC6

14.1%

AU Biotechs

-0.3%

AU Market

Return vs Industry: NC6 underperformed the Australian Biotechs industry which returned 14.1% over the past year.

Return vs Market: NC6 underperformed the Australian Market which returned -0.3% over the past year.


Shareholder returns

NC6IndustryMarket
7 Day-1.6%2.8%2.3%
30 Day-12.9%8.5%7.2%
90 Day8.9%9.2%8.7%
1 Year-3.7%-12.9%15.2%14.1%3.1%-0.3%
3 Year-64.5%-67.9%124.9%117.5%24.2%8.8%
5 Yearn/a228.6%208.9%55.4%24.4%

Long-Term Price Volatility Vs. Market

How volatile is Nanollose's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Nanollose undervalued compared to its fair value and its price relative to the market?

8.22x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NC6's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NC6's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NC6 is unprofitable, so we can't compare its PE Ratio to the XX Biotechs industry average.

PE vs Market: NC6 is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NC6's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NC6 is overvalued based on its PB Ratio (8.2x) compared to the AU Biotechs industry average (6.4x).


Next Steps

Future Growth

How is Nanollose forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nanollose has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Nanollose performed over the past 5 years?

-26.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NC6 is currently unprofitable.

Growing Profit Margin: NC6 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NC6 is unprofitable, and losses have increased over the past 5 years at a rate of 26.9% per year.

Accelerating Growth: Unable to compare NC6's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NC6 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (9%).


Return on Equity

High ROE: NC6 has a negative Return on Equity (-157.34%), as it is currently unprofitable.


Next Steps

Financial Health

How is Nanollose's financial position?


Financial Position Analysis

Short Term Liabilities: NC6's short term assets (A$929.5K) exceed its short term liabilities (A$225.3K).

Long Term Liabilities: NC6's short term assets (A$929.5K) exceed its long term liabilities (A$11.4K).


Debt to Equity History and Analysis

Debt Level: NC6's debt to equity ratio (2.6%) is considered satisfactory.

Reducing Debt: NC6 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NC6 has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: NC6 is forecast to have sufficient cash runway for 9 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Nanollose current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NC6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NC6's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NC6's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NC6's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NC6's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average board tenure


CEO

Alfie Germano

no data

Tenure

AU$326,386

Compensation

Mr. Raffaele Germano, also known as Alfie, has been Managing Director of Nanollose Limited since August 9, 2017 and also serves as its Chief Executive Officer. Mr. Germano is responsible for the operations...


CEO Compensation Analysis

Compensation vs Market: Alfie's total compensation ($USD239.95K) is about average for companies of similar size in the Australian market ($USD277.79K).

Compensation vs Earnings: Alfie's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Wayne Best
Executive Chairmanno dataAU$323.87k5.03%
A$ 366.9k
Raffaele Germano
CEO, MD & Directorno dataAU$326.39k0.42%
A$ 31.0k
Winton Willesee
Non-Executive Directorno dataAU$35.00k4.75%
A$ 346.8k
Terence William Walsh
Non-Executive Director4.25yrsAU$35.00k0.42%
A$ 31.0k
Heidi Beatty
Independent Non-Executive Director1.33yrsAU$34.34kno data

3.3yrs

Average Tenure

Experienced Board: NC6's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 57%.


Top Shareholders

Company Information

Nanollose Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nanollose Limited
  • Ticker: NC6
  • Exchange: ASX
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$7.300m
  • Shares outstanding: 117.75m
  • Website: https://www.nanollose.com

Location

  • Nanollose Limited
  • CPC
  • Suite 5
  • Nedlands
  • Western Australia
  • 6009
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NC6ASX (Australian Securities Exchange)YesOrdinary SharesAUAUDOct 2017
NC6CHIA (Chi-X Australia)YesOrdinary SharesAUAUDOct 2017

Biography

Nanollose Limited, a biotechnology company, engages in the research and development, and promotion of the microbial nanocellulose technology in Australia. It focuses on the development of Nullarbor, a plan...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/25 10:41
End of Day Share Price2020/11/25 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.